

Cure Cancer Australia Foundation Researchers to be funded in 2012

Co-funder	Recipient		Cancer Type	Lay Title	Institute	State
PdCCRS						
1033781	Christopher	Scarlett	Pancreatic (upper GI) cancer	The therapeutic potential of targeting S100A2 calcium-binding protein in pancreatic cancer	Garvan Institute of Medical Research	NSW
1030040	Carolyn	McNees	Basic science	The role of Single Stranded DNA Binding Proteins in the Alternative Lengthening of Telomeres mechanism	CMRI University of Sydney	NSW
1034715	Paul	Neilsen	Sarcoma	Reactivating the p53 pathway as a novel therapeutic approach to cancer treatment	University of Adelaide	SA
1034730	Jason	Waithman	Skin (melanoma)	The initiation of the cellular immune response to cutaneous melanoma	Ludwig Institute for Cancer Research	VIC
1021331	Justin	Lees	Glioblastoma	Inhibition of Glioblastoma Invasion by Novel Dynamin Ring Stabilisers	University of Sydney	NSW
1034561	Akira	Nguyen	Breast cancer	The role of p53-regulated microRNAs in epithelial to mesenchymal transition, and their potential as therapeutic targets against metastatic breast cancer	Garvan Institute of Medical Research	NSW
1026790	Vivien	Chen	Not tumour stream specific	Thromboembolism in Cancer	University of New South Wales	NSW
1030408	Hamish	Campbell	Basic science	Mechanism of $\Delta 133p53$ isoform oncogenicity	University of Sydney	NSW
1031971	Rajvinder	Singh	Oesophageal (upper GI) cancer	A novel method to detect and characterise dysplasia and early cancer in Barrett's oesophagus	University of Adelaide	SA
1031303	Bryan	Day	Glioma	Salinomycin a potential glioma stem cell targeting therapy	Queensland Institute of Medical Research	QLD
1032891	Randy	Suryadinata	Basic science	Cumulative cyclin-dependent kinase-mediated phosphorylation of pRb and RBP1 tumor suppressors controls cell cycle progression.	St. Vincent's Institute	VIC
1028650	Yuanyuan	Ge	Not tumour stream specific	Treating deforming tumours with real-time adaptive radiotherapy	University of Sydney	NSW

CCAF	Recipient		Cancer Type	Lay Title	Institute	State
1026823	Phoebe	Phillips	Pancreatic	The Role of β III-Tubulin in Pancreatic Stellate Cell Survival in Pancreatic Cancer	University of New South Wales	NSW
1031102	Emma	Baker	Bone	Epigenetic signatures of Osteosarcoma	St. Vincent's Institute	VIC
1034550	Jamie	Nourse	Basic science	The role of Epstein Barr Virus latency genes in the post-transcriptional regulation of microRNA biogenesis during B-cell differentiation and transformation	Queensland Institute of Medical Research	QLD
1029316	Viive	Howell	Skin	A random mutagenesis strategy for identification of new targets for the treatment of malignant	University of Sydney / Kolling Institute (RNSH)	NSW

Cure Cancer Australia Foundation Researchers to be funded in 2012

CCAF	Recipient		Cancer Type	Lay Title	Institute	State
				melanoma		
1034455	Rose	Boutros	Basic science	Role of CDK2 and PLK4 kinases in regulating centrosome duplication and their effects on tumourigenesis	University of Sydney / CMRI	NSW
1033322	Andy	Hsu	Basic science	Exploring tumour induced inhibitory receptors on immune cells	University of Melbourne	NSW
1034798	Andreas	Behren	Skin	Identification and targetting of melanoma cells undergoing EMT to interfere with metastasis and chemoresistance	Ludwig Institute for Cancer Research	VIC
1027153	Daniel	Speidel	Chemotherapy	DNA damage induced cell cycle alterations: how significant are they for tumour suppression and the response of different tissues to cytotoxic agents in vivo?	University of Sydney	NSW
1031189	Rachael	Rutkowski	Ovarian	The role of MYCN in mouse models of high-grade serous epithelial ovarian cancer	Walter and Eliza Hall Institute	VIC
1033816	Jacqueline	Donoghue	Brain	The anti tumor activity of AMG706 in glioma cell lines and xenografts alone or in combination with Panitumumab and AMG102	Monash University	VIC

Co-funder	Recipient		Cancer Type	Lay Title	Institute	State
NBCF						
PF-12-08	Heidi	Hilton	Breast Start Date: 01-01-2012	Cell type specificity of progesterone action in the normal human breast and in breast cancer	USYD Westmead Institute for Cancer Research	NSW
PF-12-14	Clare Yan	Slaney	Breast Start Date: 01-01-2012	Blocking breast cancer cell Type I IFN signalling prevents immune recognition and allows metastatic progression to bone	Peter Mac / University of Melbourne	VIC
PF-12-06	David	Gallego Ortega	Breast Start Date: 01-01-2012	An Elf5-driven transcriptional network promotes anti-estrogen therapy resistance	Garvan Institute of Medical Research	NSW

Co-funder	Recipient		Cancer Type	Lay Title	Institute	State
CCNSW						
1030430	Nicole	Verrills	Leukaemia	Activating a tumour suppressor for leukaemia therapy	University of Newcastle	NSW

Cure Cancer Australia Foundation Researchers to be funded in 2012

Co-funder	Recipient		Cancer Type	Lay Title	Institute	State
LFA						
	Santi	Suryani	Leukaemia	Improving the treatment of childhood acute leukaemia with targeted therapy of novel mutations	UNSW - Children's Cancer Institute Australia for Medical Research	NSW
	Megan	Bywater	Leukaemia	Predicting clinical success of a novel inhibitor of ribosomal RNA synthesis	Peter Mac	VIC

Co-funder	Recipient		Cancer Type	Lay Title	Institute	State
PCFA						
YI 1611	Helen	Pearson	Prostate	Investigating the role of Planar cell polarity in prostate cancer	University of Melbourne / Peter Mac	VIC
YI 2011	Jason	Dowling	Prostate	Development of high precision MRI based prostate cancer radiation therapy	CSIRO Australian e-Health Research Centre (Brisbane)	QLD